Meiling biology appeared in 2018 Guangzhou International Biotechnology Exhibition, caring for life and health!

[chinapharma.com news 】In recent years, the development of biotechnology enterprises in the Pearl River Delta has become more and more stable, and there is still room for future growth in the biomedical sector As a traditional risk averse sector, the pharmaceutical industry has been frequently supported by the state's new industrial policies Some institutions have pulled away from the high concentration of Baima shares to find new reservoirs and continue to build positions in this sector to supplement sufficient funds Guangzhou is further improving We will improve the spatial layout of the biomedical industry and speed up our efforts to seize the commanding heights of the global biomedical industry
In order to let more enterprises know about the industry, "2018 China (Guangzhou) International Biotechnology Expo" jointly held by China Association for the promotion of international science and technology, Guangdong hi tech Enterprise Association, Guangdong Pharmaceutical Association, Guangdong society of Microbiology, Guangdong Biological Industry Association, gene industry university research capital alliance, Shenzhen biological medicine promotion association and Zhenwei Exhibition Co., Ltd will be held on September 14-16 Held at the exhibition hall of Guangzhou Import and Export Fair In this exhibition, it is expected that the number of purchasers will exceed 20000 The purchasers are all from medical institutions, biological research and development companies, pharmaceutical companies, colleges and universities, investment companies, scientific research institutes, business associations, etc the professional counterparts will directly bring customers to the exhibitors and realize resource docking As a well-known enterprise in the biomedical industry, Meiling biomedical made a high-profile appearance at 2018 Guangzhou (International) biotechnology Expo, striving to find target customers in the exhibition and improve the reputation of the enterprise Meiling biomedical has three business sectors: Life Science, family health and smart cold chain At present, its main businesses include: low temperature, ultra-low temperature storage equipment, storage consumables, equipment monitoring, professional cold storage and other terminal products such as medical, laboratory and family health; as well as biological sample freezing management, wireless Intelligent Cloud monitoring, cold chain storage logistics, etc System solution business The perfect channel and after-sales service system covers more than 30 provincial administrative regions, more than 300 prefecture level administrative regions and more than 2800 county-level administrative regions At the same time, the products have obtained CE, UL and other certification, and widely serve hundreds of millions of families, medical systems, blood systems, disease control systems, health systems, animal husbandry systems, major universities, scientific research institutes, biomedical enterprises, as well as genetic engineering, life sciences and other fields Meiling officially launched the new third board on February 24, 2016 While promoting the iteration of product upgrading, it has realized product category diversification and transaction mode diversification Committed to providing users with more products and services! Many listed companies choose to participate in the 2018 Guangzhou Biotechnology Exhibition, a large part of which comes from the confidence given by the government and the market On June 6, Guangzhou International bio island once again ushered in a wave of industrial waves Nine heavyweight bio pharmaceutical industry projects were signed, five projects were started and opened With a total investment of more than 20 billion yuan, Guangzhou International bio island made a brave impact on the output value and operating revenue target of more than 100 billion yuan With the implementation of the development plan of Guangdong, Hong Kong and Macao Bay area, Guangzhou will become one of the eye-catching focuses in this blueprint It will act quickly to grow and strengthen the biomedical industry, and with more and more projects of "strong cooperation" with Chinese and foreign academicians, Guangzhou can be regarded as one of the "attractive cities in the eyes of academicians" As of 2017, there are 115 academicians in Guangzhou, including 14 Foreign academicians They will take biomedicine as a breakthrough in the industry and promote the improvement of regional independent innovation ability It is understood that Guangzhou still has a new goal this year, striving to cultivate 20 reserve talents for academicians of the "two academies" within five years Talents gathering industry, "academician economy" has become a strong engine of innovation and development in Guangzhou Biopharmaceutics has maintained a rapid growth There are nearly 150 enterprises gathered in Guangzhou bio island By 2017, the total output value of bio Island Park was 5.353 billion yuan The talent has been gradually equipped and improved The increase of R & D personnel means that Guangzhou's comprehensive competitiveness is constantly improving, and it also has the strength to compete for a place in the global market At present, the global biopharmaceutical market is more than 200 billion US dollars and still keeps rapid growth As a branch of biological medicine, the global sales of antibody drugs increased from less than $50 billion in 2011 to $106 billion in 2017, with a compound growth rate of 11.50% in seven years
At present, China's biological enterprises still focus on biological similar drugs From the perspective of the current market, China's late development advantage is obvious Because the research and development of biological similar drugs can save clinical phase II, the efficiency is greatly improved Because of China's drug review reform, the speed of drug approval is improved, and China's biological similar drug registration path is clear, which lays a foundation for the listing of biological similar drugs No matter the government or the enterprise, they attach importance to the R & D talents, the continuous influx of funds, and the clinical promotion of heavy-duty products With the fierce market competition at home and abroad, enterprises need to constantly adjust their strategies to adapt to the changes in the market Guangzhou biotechnology Expo will become the "wind vane" for enterprises to understand the frontier market At the same time, a number of conferences and forums will gather experts from various industries to provide suggestions for the rapid development of biotechnology industry For more details about "2018 China (Guangzhou) International Biotechnology Expo", please consult the organizing committee.